I joined the DIL group in May 2018 working as ITAD (Interleukin-2 Therapy of Autoimmunity in Diabetes) Trial Manager. My role is to ensure that the trial runs smoothly and to agreed timelines, by collaborating with researchers, doctors, nurses and vendors. I also support other studies and trials at the DIL.
I have been working in trial management since 2012, mostly in oncology setting. I am currently very interested in paediatric research.
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial
Marcovecchio ML. et al, (2020), Wellcome Open Research, 5, 49 - 49
Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
Roberts C. et al, (2019), British journal of cancer
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol
Nicum S. et al, (2014), BMC Cancer, 14